<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2868">
  <stage>Registered</stage>
  <submitdate>10/08/2010</submitdate>
  <approvaldate>10/08/2010</approvaldate>
  <nctid>NCT01180634</nctid>
  <trial_identification>
    <studytitle>MP-376 (Aeroquin, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis</studytitle>
    <scientifictitle>A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of MP-376 (Levofloxacin Inhalation Solution; Aeroquin) In Stable Cystic Fibrosis Patients</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Mpex-207</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cystic Fibrosis</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Connective tissue diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Cystic fibrosis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - MP-376 (Levofloxacin solution for Inhalation)
Treatment: drugs - Placebo

Experimental: 1 - Inhaled MP-376 (Aeroquin)

Placebo Comparator: 2 - Placebo


Treatment: drugs: MP-376 (Levofloxacin solution for Inhalation)
240 mg of MP-376 administered BID for 28 days

Treatment: drugs: Placebo
same volume and frequency as study drug

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Time to an exacerbation</outcome>
      <timepoint>56 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Time to administration of other anti-pseudomonal antimicrobials</outcome>
      <timepoint>56 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluate changes in FEV1, FEF 25-75 and FVC from baseline to end of treatment</outcome>
      <timepoint>28 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in bacterial load and susceptibility patterns of isolated organisms from baseline to end of treatment</outcome>
      <timepoint>28 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in respiratory domain of CFQ-R from baseline to end of treatment baseline to end of treatment</outcome>
      <timepoint>28 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluate the safety of MP-376 administered over 28 days, compared to placebo</outcome>
      <timepoint>56 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion Criteria (selected):

          -  &gt;/= 12 years of age

          -  Confirmed Diagnosis of Cystic Fibrosis

          -  Positive sputum culture for P. aeruginosa at screening and within the past 12 months

          -  Patients are able to elicit an FEV1 &gt;/= 25% but &lt;/= 85% of predicted value at
             screening

          -  Have received at least 3 courses of inhaled antimicrobials over the preceding 12
             months

          -  Clinically stable with no changes in health status within the last 28 days

          -  Able to reproducibly produce sputum and perform spirometry</inclusivecriteria>
    <inclusiveminage>12</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion Criteria (selected):

          -  Use of any nebulized or systemic antibiotics within 28 days prior to baseline

          -  History of hypersensitivity to fluoroquinolones or intolerance with aerosol medication

          -  Evidence of respiratory infections within 14 days prior to dosing

          -  CrCl &lt; 20ml/min or &lt; 20ml/min/1.73 m2 at Screening</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>330</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC</recruitmentstate>
    <hospital>Westmead Chilren's Hospital - Westmead</hospital>
    <hospital>Westmead Hospital - Westmead</hospital>
    <hospital>Mater Miscericordiae Hospital - Brisbane</hospital>
    <hospital> - Brisbane</hospital>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Royal Children's Hospital - Melbourne</hospital>
    <hospital>The Alfred Hospital - Melbourne</hospital>
    <hospital>Monash Medical Center - Melbourne</hospital>
    <hospital>John Hunter Hospital - New South Wales</hospital>
    <postcode> - Westmead</postcode>
    <postcode> - Brisbane</postcode>
    <postcode> - Adelaide</postcode>
    <postcode> - Melbourne</postcode>
    <postcode> - New South Wales</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alaska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Delaware</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Idaho</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maine</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Mississippi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Hampshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Dakota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Vermont</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>West Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Haifa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Jerusalem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Petah Tikva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Ramat-Gan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Forest Laboratories</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Patients with cystic fibrosis (CF) suffer from chronic infections of the lower respiratory
      tract that can be caused by one or multiple bacteria, including Pseudomonas aeruginosa, which
      has been particularly problematic to eradicate and been implicated as the major cause of
      morbidity and mortality in CF patients. Aerosol delivery of antibiotics directly to the lung
      increases the local concentrations of antibiotic at the site of infection resulting in
      improved antimicrobial effects compared to systemic administration. Decreased efficacy,
      intolerance and high treatment burden with currently available therapies indicate a need for
      additional therapies. MP-376 (Aeroquin) is a novel formulation of the fluoroquinolone
      levofloxacin that has been optimized for aerosol delivery. Preclinical and clinical studies
      conducted to date show that aerosol doses of MP-376 are safe and well tolerated, exert an
      antimicrobial effect, improve lung function and reduce the need for other anti-pseudomonal
      antibiotics. High concentrations of levofloxacin in the lung delivered as MP-376 are active
      against CF pathogens including those with high minimum inhibitory concentration (MIC) levels
      to aminoglycosides such as tobramycin (TOBI®) and other inhaled antimicrobial agents. Inhaled
      MP-376 can be delivered rapidly and efficiently using a customized PARI investigational
      configuration of the eFlow® nebulizer system.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01180634</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Patrick Flume, M.D.</name>
      <address>Medical University of South Carolina</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>